Loganin (cas 18524-94-2) possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy
-
Add time:09/09/2019 Source:sciencedirect.com
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by motor neurons degeneration and muscular atrophy. There is no effective SMA treatment. Loganin (cas 18524-94-2) is a botanical candidate with anti-inflammatory, anti-oxidant, glucose-lowering and anti-diabetic nephropathy activities. The aim of this study is to investigate the potential protective effects of loganin on SMA using two cellular models, SMN-deficient NSC34 cells and SMA patient fibroblasts, and an animal disease model, SMAο7 mice. In SMN-deficient NSC34 cells, loganin increased cell viability, neurite length, and expressions of SMN, Gemin2, SMN-Gemin2 complex, p-Akt, p-GSK-3β, p-CREB, BDNF and Bcl-2. However, both AG1024 (IGF-1 R antagonist) and IGF-1 R siRNA attenuated the protective effects of loganin on SMN level and cell viability in SMN-deficient NSC34 cells. In SMA patient fibroblasts, loganin up-regulated levels of SMN, FL-SMN2, and Gemins, increased numbers of SMN-containing nuclear gems, modulated splicing factors, and up-regulated p-Akt. Furthermore, in the brain, spinal cord and gastrocnemius muscle of SMAο7 mice, loganin up-regulated the expressions of SMN and p-Akt. Results from righting reflex and hind-limb suspension tests indicated loganin improved muscle strength of SMAο7 mice; moreover, loganin activated Akt/mTOR signal and inhibited atrogin-1/MuRF-1 signal in gastrocnemius muscle of SMAο7 mice. Loganin also increased body weight, but the average lifespan of loganin (20 mg/kg/day)-treated SMA mice was 16.80 ± 0.73 days, while saline-treated SMA mice was 10.91 ± 0.96 days. In conclusion, the present results demonstrate that loganin provides benefits to SMA therapeutics via improving SMN restoration, muscle strength and body weight. IGF-1 plays an important role in loganin neuroprotection. Loganin can be therefore a valuable complementary candidate for treatment of neuromuscular diseases via regulation of muscle protein synthesis and neuroprotection.
We also recommend Trading Suppliers and Manufacturers of Loganin (cas 18524-94-2). Pls Click Website Link as below: cas 18524-94-2 suppliers
Prev:Endocrine pharmacologyLoganin (cas 18524-94-2) protects against pancreatitis by inhibiting NF-κB activation
Next:Loganin (cas 18524-94-2) enhances long-term potentiation and recovers scopolamine-induced learning and memory impairments) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Loganin (cas 18524-94-2) protects against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells09/27/2019
- Hepato-protective effects of Loganin (cas 18524-94-2), iridoid glycoside from Corni Fructus, against hyperglycemia-activated signaling pathway in liver of type 2 diabetic db/db mice09/26/2019
- Loganin (cas 18524-94-2) attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products09/25/2019
- Behavioural PharmacologyLoganin (cas 18524-94-2) improves learning and memory impairments induced by scopolamine in mice09/24/2019
- Loganin (cas 18524-94-2) enhances long-term potentiation and recovers scopolamine-induced learning and memory impairments09/10/2019
- Endocrine pharmacologyLoganin (cas 18524-94-2) protects against pancreatitis by inhibiting NF-κB activation09/08/2019
- Effect of Loganin (cas 18524-94-2) on experimental diabetic nephropathy09/07/2019
- Parentucellia latifolia subsp. latifolia: A potential source for Loganin (cas 18524-94-2) iridoids by HPLC-ESI-MSn technique09/06/2019
- Loganin (cas 18524-94-2) inhibits the inflammatory response in mouse 3T3L1 adipocytes and mouse model☆09/05/2019